TVB-2640
TVB-2640 is an oral, selective fatty acid synthase (FASN) inhibitor. It reduces hepatic de novo lipogenesis in males with metabolic abnormalities. It is being evaluated in phase 2 clinical trials to treat KRAS mutant non-small cell lung carcinomas.
Product Specifications
Shipping Conditions
Gel Pack
Storage Conditions
-20ºC
Shelf Life
36 months
More Discoveries
Explore Other Products
Browse additional items from our catalog
bs-4154R-APC-Cy5.5 100 µL
PTPRA Polyclonal Antibody, APC-Cy5.5 Conjugated
Sign In for Pricing
View Details 
MBS1413164 Inquire
Recombinant Rhizobium leguminosarum bv.viciae Formate--tetrahydrofolate ligase (fhs), partial
Sign In for Pricing
View Details 
K3347403 1.0 µg DNA
Lrrc69 sgRNA CRISPR Lentivector (Mouse) (Target 2)
Sign In for Pricing
View Details